BullFrog AI Technology Licensed from Johns Hopkins University APL Named Finalist in R&D 100 Awards
23 August 2023 - 10:00PM
BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or
the "Company"), a precision medicine company using artificial
intelligence (AI) and machine learning to enable the successful
development of pharmaceuticals and biologics, today
announced that its machine learning/artificial intelligence
technology, exclusively licensed from the Johns Hopkins University
Applied Physics Lab (APL), has been selected as a finalist in the
IT/Electrical category for the R&D 100 Awards. The designation
recognizes APL’s Prometheus/Euclid/Seagull algorithm suite as a
leading-edge library integrating probabilistic modeling, graph
analysis, and time series analysis to solve complex data
challenges.
BullFrog AI’s proprietary bfLEAP™ AI platform
leverages the Prometheus/Euclid/Seagull algorithm suite with an aim
to enable clients to make discoveries and predictions from clinical
and real world data sets with a focus on improving and streamlining
the drug development process and the design of clinical trials.
Prometheus/Euclid/Seagull algorithm suite’s key strengths include
scalability for shallow and wide to large, high-dimensional
datasets, handling missing information, and versatility across
domains. Prometheus offers parallelizable probabilistic models
excelling in anomaly detection and clustering. Euclid stands out
with automated data fusion, link inference, and network flow
analysis. Seagull excels in enriching and correlating time series
data for anomaly detection. The suite's modular structure ensures
adaptability and applicability across domains.
"We are honored that the proprietary machine
learning technology for which we hold exclusive global licensing
rights from APL has been named a finalist for the R&D 100
Awards,” stated Vin Singh, CEO of BullFrog AI. “We believe that any
powerful solution for the pharmaceutical industry needs to lead
with great technology and this designation further validates the
best-in-class capability of our bfLEAP™ AI platform to glean
insights from incomplete data sets, in a transparent and
explainable manner, that reveal patterns and relationships to
better predict how patients and drug compounds will respond in
clinical trials.”
About BullFrog AIBullFrog AI is
a precision medicine company using AI and machine learning to
enable the successful development of pharmaceuticals and biologics
by predicting which patients will respond to therapies in
development. Through its collaborations with leading research
institutions, including Johns Hopkins University, BullFrog AI is at
the forefront of AI-driven drug development using its proprietary
bfLEAP™ artificial intelligence platform. BullFrog AI is deploying
bfLEAP™ for use at several critical stages of development with the
intention of streamlining data analytics in therapeutics
development, decreasing the overall development costs by decreasing
failure rates for new therapeutics. For more information visit
BullFrog AI at:Website: https://bullfrogai.com LinkedIn:
https://www.linkedin.com/company/bullfrogai/
Safe Harbor StatementThis press
release contains forward-looking statements. We base these
forward-looking statements on our expectations and projections
about future events, which we derive from the information currently
available to us. Such forward-looking statements relate to future
events or our future performance, including: our financial
performance and projections; our growth in revenue and earnings;
and our business prospects and opportunities. You can identify
forward-looking statements by those that are not historical in
nature, particularly those that use terminology such as "may,"
"should," "expects," "anticipates," "contemplates," "estimates,"
"believes," "plans," "projected," "predicts," "potential," or
"hopes" or the negative of these or similar terms. In evaluating
these forward-looking statements, you should consider various
factors, including: our ability to change the direction of the
Company; our ability to keep pace with new technology and changing
market needs; and the competitive environment of our business.
These and other factors may cause our actual results to differ
materially from any forward-looking statement. Forward-looking
statements are only predictions. The forward-looking events
discussed in this press release and other statements made from time
to time by us or our representatives, may not occur, and actual
events and results may differ materially and are subject to risks,
uncertainties, and assumptions about us. We are not obligated to
publicly update or revise any forward-looking statement, whether as
a result of uncertainties and assumptions, the forward-looking
events discussed in this press release and other statements made
from time to time by us or our representatives might not occur.
Contact:InvestorsDave
GentryRedChip Companies, Inc.BFRG@redchip.com800-733-2447
MediaTiberend Strategic Advisors, Inc.Eric
ReissEreiss@tiberend.com802-249-1136
Dave SchemeliaDschemelia@tiberend.com609-468-9325
SOURCE: BullFrog AI Holdings,
Inc.
Bullfrog AI (NASDAQ:BFRGW)
Historical Stock Chart
From Jun 2024 to Jul 2024
Bullfrog AI (NASDAQ:BFRGW)
Historical Stock Chart
From Jul 2023 to Jul 2024